Loading company details...
Beta
Latest Form 4 (Oct 16, 2026): James N. Wilson (Director): Sale of 6,654 shares, $761.7K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 16, 2026 | James N. Wilson | Sale | 6,654 | $761.7K |
| Oct 5, 2026 | Roberto Wandenkolk Vieira, President, Oncology | Exercise/Conversion | 8,333 | $180.2K |
| Oct 5, 2026 | Joseph Douglas Lyon, Chief Accounting & Technology Officer | Exercise/Conversion | 810 | $11.0K |
| Oct 5, 2026 | Sean Maduck | Exercise/Conversion | 413 | $3.4K |
| Oct 5, 2026 | Justin Frederick Gunn | Grant/Award | 100,000 | n/a |
| Sep 28, 2026 | Gary Charles Robb, Chief Business Officer | Gift | 17,100 | n/a |
| Sep 18, 2026 | Roberto Wandenkolk Vieira, President, Oncology | Sale | 296 | $29.8K |
| Sep 18, 2026 | Gary Charles Robb, Chief Business Officer | Exercise/Conversion | 17,493 | $144.7K |
| Sep 16, 2026 | Joseph Douglas Lyon, Chief Accounting & Technology Officer | Exercise/Conversion | 2,596 | $29.5K |
| Sep 16, 2026 | James N. Wilson | Sale | 6,800 | $749.8K |